• Explore /
  • Poster
  • / A randomized phase 2 trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM): Feasibility and safety outcomes (the VERTU study).

A randomized phase 2 trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM): Feasibility and safety outcomes (the VERTU study).

Abstract Poster

Authors

Mustafa Khasraw

Mustafa Khasraw

Royal North Shore Hospital/ University of Sydney, St Leonards, Australia

Mustafa Khasraw , Kerrie Leanne McDonald , Mark Rosenthal , Zarnie Lwin , David M. Ashley , Helen Wheeler , Elizabeth Barnes , Eng-Siew Koh , Matthew C Foote , Michael Buckland , Lauren Fisher , Robyn Leonard , Merryn Hall , Sonia Yip , John Simes

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Central Nervous System Tumors

Track

Central Nervous System Tumors

Sub Track

Central Nervous System Tumors

Clinical Trial Registration Number

12615000407594

Citation

J Clin Oncol 36, 2018 (suppl; abstr 2045)

DOI

10.1200/JCO.2018.36.15_suppl.2045

Abstract #

2045

Poster Bd #

203

Abstract Disclosures

Similar Posters

First Author: Mustafa Khasraw

First Author: Hao-Wen Sim

First Author: Paul James Mulholland

First Author: Dorota Goplen